Clinical Trials Browser

Phase 2 × Hypergammaglobulinemia × daratumumab × Clear all

NCT03679624 2023-10-23

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Phase 2 Terminated

1 enrolled 8 charts

Hypergammaglobulinemia, Waldenstrom Macroglobulinemia, Recurrence